九洲药业(603456.SH)：甲苯磺酸艾多沙班化学原料药上市申请获批准

Core Viewpoint - Jiuzhou Pharmaceutical (603456.SH) has received the approval notice for the marketing application of Tofisopam Tosylate from the National Medical Products Administration, marking a significant milestone for the company in the oral anticoagulant market [1] Group 1 - The approved drug, Tofisopam Tosylate, is an oral anticoagulant primarily used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation [1] - The drug is also indicated for the treatment or prevention of deep vein thrombosis and pulmonary embolism [1]